ARTICLE | Company News
NICE backs Prolia
September 16, 2010 1:14 AM UTC
The U.K.'s NICE issued a final appraisal determination recommending the use of Prolia denosumab from Amgen Inc. (NASDAQ:AMGN) for the primary and secondary prevention of osteoporotic fragility fractur...